Testosterone therapy is often marketed like a switch. For women after menopause asking how quickly testosterone therapy works, the evidence-backed answer is slower and narrower.
For carefully assessed hypoactive sexual desire disorder, International Society for the Study of Women's Sexual Health says average efficacy emerges about 6 to 8 weeks after starting therapy, many women feel improvement after 4 weeks, maximal effects in sexual desire and satisfactory sexual events occur around 12 weeks, and therapy should not continue beyond 6 months without clinically meaningful improvement. [1]
That answer only applies to the right target. Testosterone is not an established quick fix for fatigue, weight, mood, muscle, brain fog, or anti-aging. The Global Consensus Position Statement says the only evidence-based indication for testosterone therapy in women is hypoactive sexual desire disorder after menopause, using a biopsychosocial assessment model. [2]
The practical timeline
The timeline has two parallel tracks: benefit and safety monitoring.
| Time point | What to expect | What not to assume |
|---|---|---|
| Before starting | hypoactive sexual desire disorder diagnosis, distress, contributors, baseline total testosterone, sex hormone-binding globulin, and safety context are reviewed. [1] | A low testosterone result alone confirms therapy is needed. |
| 3 to 6 weeks | Total testosterone is checked to avoid excessive exposure and guide adjustment. [1] | A higher number is the treatment goal. |
| About 4 weeks | Some women feel improvement, and sexually associated distress may begin to decline. [1] | Everyone should feel a dramatic change by week 4. |
| 6 to 8 weeks | Average efficacy emerges in clinical-trial data summarized by International Society for the Study of Women's Sexual Health. [1] | Lack of a clear response by week 6 means the dose should be pushed above the female range. |
| About 12 weeks | Maximal effects in sexual desire and satisfactory sexual events occur around this point. [1] | Benefits should be judged from libido alone without distress, pain, sleep, medication, and relationship context. |
| By 6 months | If there is no clinically meaningful improvement, treatment should not continue. [1] | Continuing indefinitely without benefit is evidence-based. |
The safety check often comes before the benefit is obvious. That is intentional. The point is to prevent supraphysiologic exposure while giving the symptom enough time to respond.
What "works" should mean
For women, testosterone response is not the same as a lab number moving upward.
The strongest evidence category is low desire with distress after menopause. In a 2019 systematic review and meta-analysis of 36 randomized trials with 8,480 women, testosterone improved sexual-function outcomes in postmenopausal women, including satisfactory sexual event frequency, desire, arousal, orgasm, responsiveness, self-image, sexual concerns, and distress. The same review found more acne and hair growth, worse lipid effects with oral testosterone, no clear effect on body composition, musculoskeletal outcomes, or cognition, and no long-term safety certainty. [3]
An 814-woman 52-week randomized trial in postmenopausal women with hypoactive sexual desire disorder not using estrogen measured efficacy through week 24. The 300 mcg/day patch group had a greater increase in 4-week satisfying sexual episodes than placebo at 24 weeks, but androgenic adverse events, mainly unwanted hair growth, were more common, and long-term breast effects remained uncertain. [4]
Those data make the decision target specific: desire and distress, not general optimization.
| If "working" means | Evidence fit | Better endpoint |
|---|---|---|
| More desire with less distress after menopause | Stronger fit | Desire, distress, satisfying sexual events, and side effects over 12 weeks. |
| More energy or motivation | Poor fit | Look for sleep loss, depression, thyroid disease, anemia, medications, pain, hot flashes, or overtraining first. |
| Weight loss or better body composition | Poor fit | Use metabolic, nutrition, strength, medication, and sleep assessment instead. |
| Better mood or less anxiety | Poor fit | Treat mood, sleep, medication effects, relationship stress, trauma, or vasomotor symptoms directly. |
| A higher testosterone number | Poor fit | Keep exposure in the physiologic female range and judge symptom benefit plus harms. |
When does this timeline apply?
The timing answer fits a narrow clinical picture:
- Postmenopausal woman or late reproductive-age woman in a specialist-guided context.
- Persistent low sexual desire that causes distress.
- A biopsychosocial assessment has reviewed relationship context, mood, sleep, pain with sex, vaginal dryness, medications, alcohol, trauma history, thyroid disease, hot flashes, and other contributors.
- The product can be dosed and monitored to avoid supraphysiologic levels.
- There is a stop rule if symptoms do not meaningfully improve.
It is not a fit when the main goal is energy, confidence, weight, muscle, anti-aging, or a better lab number. The Endocrine Society guideline recommends against diagnosing an androgen deficiency syndrome in healthy women and recommends against general testosterone use for sexual dysfunction outside hypoactive sexual desire disorder, cognitive, cardiovascular, metabolic, bone, or general well-being indications. [5]
Red flags that change the plan
Some findings should pause or redirect the timeline question.
| Red flag | Why it changes the assessment |
|---|---|
| No formal hypoactive sexual desire disorder assessment | Testosterone response should not be judged before the diagnosis is clear. |
| A plan based only on "low T" | Total testosterone should not be used as a stand-alone hypoactive sexual desire disorder diagnosis. [1] |
| Dose increases above the physiologic female range | International Society for the Study of Women's Sexual Health says raising testosterone beyond the physiologic range to overcome low free testosterone is not supported. [1] |
| Acne, unwanted facial hair, scalp hair loss, voice change, clitoral symptoms, or mood changes | These can signal androgen excess or poor fit. |
| Oral testosterone, pellets, or unclear compounded dosing | Oral routes can worsen lipids, and pellets or compounded products can create dosing-control problems. [1] [3] [6] |
| Pregnancy possibility or accidental gel transfer risk | Testosterone gel labeling warns about virilization from secondary exposure and says the product is not indicated for women. [7] |
| No benefit by 6 months | International Society for the Study of Women's Sexual Health says therapy should not continue beyond 6 months without clinically meaningful improvement. [1] |
The red flags do not make testosterone categorically inappropriate. They mean the next step is a better assessment, not a higher dose.
Why the first lab check comes before the full benefit window
International Society for the Study of Women's Sexual Health recommends measuring total testosterone before therapy and again 3 to 6 weeks after initiation. If the dose is increased, total testosterone should be repeated within 6 weeks. The goal is to prevent excessive dosing, not to treat to a target testosterone level. [1]
That distinction is important. A person might not have full symptom response by week 4 or week 6, but the clinician still needs to know whether exposure is too high. When levels are supraphysiologic, androgenic effects such as acne, hirsutism, voice deepening, and androgenic alopecia become a bigger concern. [1]
The 2025 ALEG position statement reaches a similar monitoring shape: testosterone for postmenopausal women should be limited to confirmed hypoactive sexual desire disorder through formal biopsychosocial evaluation, routine serum androgen measurements are not recommended for diagnosis, monitoring should occur within 3 to 6 weeks, transdermal routes are preferred, and pellets plus compounded "bioidentical" testosterone are not recommended because of supraphysiologic dosing risk and insufficient evidence. [6]
Decision table: wait, adjust, stop, or change the target?
| Situation | More reasonable next step | Why |
|---|---|---|
| Week 4, mild improvement, no side effects, level not high | Continue planned assessment window | Some response can appear by 4 weeks, but maximal effects are closer to 12 weeks. [1] |
| Week 6, level high or side effects appear | Reduce, pause, or reassess with clinician | Safety monitoring is not optional while waiting for benefit. |
| Week 12, desire and distress clearly improved, no androgen excess | Continue with follow-up monitoring | This is the window where maximal desire and satisfactory-event effects are expected. [1] |
| Week 12, no improvement, but pain, genitourinary syndrome of menopause, sleep loss, depression, or medication effects are untreated | Reassess the diagnosis and contributors | Testosterone may be the wrong target. |
| Month 6, no meaningful benefit | Stop rather than continue indefinitely | International Society for the Study of Women's Sexual Health says not to continue beyond 6 months without meaningful improvement. [1] |
| Benefit exists but acne, hair growth, scalp shedding, voice change, or clitoral symptoms appear | Reassess dose, route, and whether continuing is worth it | Harms can erase the value of modest benefit. |
A good treatment trial has a beginning, a monitoring plan, a response endpoint, and a stop rule.
What to ask a clinician
Ask a clinician:
- Are we treating hypoactive sexual desire disorder, and how was the diagnosis made?
- What other causes of low desire have we already addressed?
- What should count as meaningful improvement by 12 weeks?
- When will total testosterone be checked, and what level is too high?
- Which side effects should make me stop or lower the dose?
- If I have no meaningful improvement by 6 months, what is the next assessment?
- Is the product doseable, adjustable, and avoidant of supraphysiologic exposure?
- How do I prevent accidental transfer if a gel is used?
These questions keep the timeline attached to the evidence rather than to marketing expectations.
Bottom line
For women after menopause with carefully assessed hypoactive sexual desire disorder, testosterone therapy usually needs weeks to months: possible improvement around 4 weeks, average efficacy around 6 to 8 weeks, maximal desire and satisfactory-event effects around 12 weeks, and a 6-month stop rule if benefit is not meaningful.
That timeline should not be borrowed for fatigue, weight, mood, muscle, cognition, or anti-aging. A clinician-screened assessment should decide whether testosterone is the right target before the clock starts.
Related reading:
- Testosterone for women after menopause.
- Testosterone gel for women.
- Testosterone monitoring for women.
- Testosterone side effects in women.
- dehydroepiandrosterone vs testosterone after menopause.
References
[1] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. https://pmc.ncbi.nlm.nih.gov/articles/PMC8064950/
[2] Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429-434. doi:10.1080/13697137.2019.1637079 https://pubmed.ncbi.nlm.nih.gov/31474158/
[3] Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/s2213-8587(19)30189-5 https://pubmed.ncbi.nlm.nih.gov/31353194/
[4] Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359(19):2005-17. doi:10.1056/nejmoa0707302 https://pubmed.ncbi.nlm.nih.gov/18987368/
[5] Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-510. doi:10.1210/jc.2014-2260 https://pubmed.ncbi.nlm.nih.gov/25279570/
[6] Pilnik S, Belardo A, Marchesan LB, et al. Androgen therapy in midlife and older women: a position statement of the Latin American Association of Gynecological Endocrinology (ALEG). Climacteric. 2025;28(5):529-536. doi:10.1080/13697137.2025.2548805 https://pubmed.ncbi.nlm.nih.gov/40919649/
[7] DailyMed. Testosterone Gel, 1.62% prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54fcdcb9-fb0e-4164-9e51-f2a5feae3217